FDA Advisory Committee recommends ATX 101(deoxycholic acid) to treat submental fat in adults.- KytheraBiopharmaceuticals Inc.
Kythera Biopharmaceuticals Inc. has announced that the FDA Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to support the approval of ATX 101 (deoxycholic acid) injection for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults, which is often referred to as a double chin. If approved, ATX 101 would be a first-in-class submental contouring injectable drug.
Comment: Submental fat (chin fat) can lead to a loss of confidence about attractiveness and can be resistant to weight loss. Current treatment options are limited to aesthetic surgical procedures or liposuction. ATX 101 offers, therefore, a less invasive approach.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins